Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.91 USD | +0.26% | -5.78% | +4.55% |
May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
Chart calendar Fate Therapeutics, Inc.
Upcoming events on Fate Therapeutics, Inc.
Past events on Fate Therapeutics, Inc.
2024-05-09 05:00 pm | Q1 2024 Earnings Call |
2024-05-09 04:01 pm | Q1 2024 Earnings Release |
2024-05-09 12:00 pm | American Society of Gene & Cell Therapy Meeting - Abstract Number : 1415 |
2024-05-07 03:00 pm | American Society of Gene & Cell Therapy Meeting - Abstract Number : 45 |
2024-04-10 02:15 pm | Needham Healthcare Conference |
2024-03-26 03:00 pm | H.C. Wainwright Cell Therapy Virtual Conference - Fireside Chat |
2024-03-12 | Jefferies Biotech on the Bay Summit |
2024-03-12 11:15 am | Barclays Global Healthcare Conference |
2024-03-11 02:00 pm | Leerink Partners Global Biopharma Conference |
2024-03-06 09:10 am | TD Cowen Health Care Conference |
2024-02-26 05:00 pm | Q4 2023 Earnings Call |
2024-02-26 04:01 pm | Q4 2023 Earnings Release |
2023-11-08 05:00 pm | Q3 2023 Earnings Call |
2023-11-08 04:01 pm | Q3 2023 Earnings Release |
2023-09-08 09:30 am | Wells Fargo Healthcare Conference - Fireside Chat |
2023-09-06 | Citi BioPharma Conference |
2023-08-08 05:00 pm | Q2 2023 Earnings Call |
2023-08-08 04:01 pm | Q2 2023 Earnings Release |
2023-06-13 05:00 pm | Goldman Sachs Global Healthcare Conference |
2023-06-07 03:30 pm | Jefferies Global Healthcare Conference |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 10,7 9,62 11.03% | 31,4 20,6 52.54% | 55,8 51,4 8.69% | 96,3 69,1 39.4% | 63,5 63,4 0.2% | 6,12 |
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | -211 -215 1.94% | -295 -321 8.31% | -172 -185 7.15% | -198 |
EBIT Million USD | Released Forecast Spread | -101 -99,9 -0.82% | -128 -130 1.34% | -217 -202 -7.16% | -308 -329 6.17% | -191 -195 2.5% | -212 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -98,1 -97,4 -0.72% | -173 -146 -18.8% | -212 -206 -2.82% | -282 -309 8.83% | -161 -167 3.82% | -202 |
Net income Million USD | Released Forecast Spread | -98,1 -97,8 -0.4% | -173 -147 -17.96% | -212 -208 -1.84% | -282 -309 8.69% | -161 -168 4.19% | -202 |
EPS USD | Released Forecast Spread | -1,44 -1,44 0.21% | -2,10 -1,82 -15.58% | -2,24 -2,21 -1.39% | -2,91 -3,20 9.02% | -1,64 -1,71 4.3% | -1,77 |
Announcement Date | 02/03/20 | 24/02/21 | 28/02/22 | 28/02/23 | 26/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 18,4 9,01 104.34% | 18,5 12,6 47.66% | 15,0 15,5 -3.26% | 44,4 18,4 140.97% | 59,0 33,5 75.9% | 0,93 5,74 -83.75% | 1,94 0,90 116% | 1,68 1,53 9.7% | 1,93 1,26 52.78% | 1,60 | 1,34 | 1,43 | 1,40 | 1,40 |
EBITDA Million USD | Released Forecast Spread | -43,2 -48,4 10.73% | -46,2 -49,0 5.62% | -47,9 | -48,4 | -49,0 | |||||||||
EBIT Million USD | Released Forecast Spread | -74,5 -76,2 2.28% | -83,1 -82,2 -1.15% | -86,4 -88,4 2.3% | -64,4 -85,3 24.48% | -28,6 -61,5 53.52% | -62,6 -61,7 -1.33% | -51,3 -60,3 14.95% | -48,1 -55,2 12.93% | -51,1 -50,6 -0.83% | -52,2 | -54,0 | -54,8 | -53,5 | -56,0 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -65,7 -75,3 12.72% | -76,1 -80,3 5.28% | -83,6 -85,9 2.68% | -56,4 -83,6 32.62% | -18,9 -67,9 72.19% | -52,8 -60,2 12.33% | -45,2 -57,3 21.24% | -44,1 -50,5 12.68% | -48,0 -46,8 -2.56% | -49,6 | -51,7 | -52,7 | -52,5 | -55,1 |
Net income Million USD | Released Forecast Spread | -65,7 -76,0 13.52% | -76,1 -81,0 6.01% | -83,6 -87,7 4.69% | -56,4 -82,7 31.85% | -18,9 -65,9 71.36% | -52,8 -58,9 10.37% | -45,2 -57,6 21.62% | -44,1 -51,6 14.57% | -48,0 -46,8 -2.58% | -49,6 | -51,7 | -52,6 | -52,4 | -55,2 |
EPS USD | Released Forecast Spread | -0,68 -0,79 13.85% | -0,78 -0,83 5.9% | -0,86 -0,90 4.51% | -0,58 -0,87 33.03% | -0,19 -0,66 70.99% | -0,54 -0,60 9.58% | -0,46 -0,58 21.11% | -0,45 -0,53 15.19% | -0,47 -0,47 -0.9% | -0,46 | -0,48 | -0,47 | -0,46 | -0,47 |
Announcement Date | 04/05/22 | 03/08/22 | 03/11/22 | 28/02/23 | 03/05/23 | 08/08/23 | 08/11/23 | 26/02/24 | 09/05/24 | - | - | - | - | - |
Past sector events for Fate Therapeutics, Inc.
2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
2024-05-15 04:01 pm | CELCUITY INC.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 08:00 am | IMMUNOME, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- FATE Stock
- Calendar Fate Therapeutics, Inc.